ADMP - Adamis Pharmaceuticals Corp.
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
25%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 7.37%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -170.82%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 0.97
Debt Ratio is 0.42
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.22
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Adamis Pharmaceuticals Corp. (ADMP) - http://www.adamispharmaceuticals.com
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.Exchange - NASDAQ
Industry - Pharmaceuticals: Major
Sector - Health Technology
CEO - Dennis J. Carlo
Employees - 171
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.